XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Total revenue $ 1,011,560 $ 1,029,373
Costs and expenses:    
Cost of revenue (excluding amortization of intangible assets) 666,717 651,719
Selling, general and administrative 186,291 174,846
Amortization of intangible assets 32,575 34,916
Operating income 125,977 167,892
Other income (expense):    
Interest income 2,202 806
Interest expense (35,001) (34,380)
Other income (expense), net 5,833 (3,277)
Income before income taxes 99,011 131,041
Provision for income taxes 24,529 27,087
Net income 74,482 103,954
Less: Net income attributable to noncontrolling interests 1,522 823
Net income available to Charles River Laboratories International, Inc. 72,960 103,131
Preferred Stock Dividends and Other Adjustments [Abstract]    
Net income available to Charles River Laboratories International, Inc. 72,960 103,131
Less: Adjustment of redeemable noncontrolling interest 401 0
Less: Incremental dividends attributable to noncontrolling interest holders 5,230 0
Net income available to Charles River Laboratories International, Inc. common shareholders $ 67,329 $ 103,131
Net income attributable to common shareholders:    
Basic (in dollars per share) $ 1.31 $ 2.02
Diluted (in dollars per share) $ 1.30 $ 2.01
Weighted-average number of common shares outstanding:    
Basic (in shares) 51,437 51,097
Diluted (in shares) 51,842 51,428
Cost of services provided (excluding amortization of intangible assets)    
Total revenue $ 816,862 $ 857,366
Costs and expenses:    
Cost of revenue (excluding amortization of intangible assets) 578,164 565,477
Cost of products sold (excluding amortization of intangible assets)    
Total revenue 194,698 172,007
Costs and expenses:    
Cost of revenue (excluding amortization of intangible assets) $ 88,553 $ 86,242